Leopoldo Santos-Argumedo, Ricardo U. Sorensen, Edgar Borges de Oliveira-Júnior, Antonio Condino-Neto, Francisco J. Espinosa-Rosales, Stefanie Klaver, Wilma Carvalho Neves Forte, Julio Orellana, Otavio Cabral-Marques, Silvia Danielian, Carolina Prando, Liliana Bezrodnik, Miguel Galicchio, Lena Friederick Schimke, Dino Pietropaolo-Cienfuegos, Alejandra King, Lizbeth Blancas-Galicia, Beatriz Tavares Costa-Carvalho, Jacinta Bustamante, Anete Sevciovic Grumach, Nuria Bengala Zurro, Matías Oleastro, Marcia Buzolin, Oscar Porras, Alejandro Lozano, Paulo Vitor Soeiro Pereira, Lorena Regairaz, and Pérsio Roxo-Junior
(59.4%), granulomata (49.3%), skin infections (42%), chronic diarrhea (41.9%), otitis (29%), sepsis (23.2%), abscesses (21.7%), recurrent urinary tract infection (20.3%), and osteomyelitis (15.9%). Adverse reactions to bacillus Calmette-Gu� (BCG) vaccination were identified in 30% of the studied Latin American CGD cases. The genetic diagnoses of the 71 patients revealed 53 patients from 47 families with heterogeneous mutations in the CYBB gene (five novel mutations:p.W361G,p.C282X,p.W483R,p.R226X,andp.Q93X),16 patientswith the commondeletionc.75_76 del.GTinexon2 ofNCF1 gene, and two patients with mutations in the CYBA gene. Conclusion. The majority of Latin American CGD patients carry a hemizygous mutation in the CYBB gene. They also presented a wide range of clinical manifestations most frequently bacterial and fungal infections of the respiratory tract, skin, and lymph nodes. Thirty percent of the Latin American CGD patients presented adverse reactions to BCG, indicating that this vaccine should be avoided in these patients. # 2015 Wiley Periodicals, Inc.